SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03284684

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Kinetics of Perioperative Circulating DNA in Cancer Surgery

The aim of this study was to determine the kinetics of perioperative circulating DNA in three types of cancer. This first step will enable further studies comparing the potential impact of certain techniques or anesthetic products on cancer surgery.

NCT03284684 Breast Cancer Prostate Cancer Colon Cancer
MeSH: Colonic Neoplasms
HPO: Colon cancer Neoplasm of the colon

1 Interventions

Name: Blood test

Description: plasma concentration of circulating DNA of specific genes

Type: Other

circulating DNA plasma level test


Primary Outcomes

Description: ng/mL in plasma

Measure: Change in concentration of total mutant circulating DNA

Time: Nine timepoints between Day-1 to Day 3

Description: ng/mL in plasma

Measure: Change in proportion of mutant circulating DNA

Time: Nine timepoints between Day-1 to Day 3

Description: concentration of long ACTB ctDNA fragments/concentration of short ACTB ctDNA fragments

Measure: Change in integrity index of circulating DNA for ACTB gene

Time: Nine timepoints between Day-1 to Day 3

Description: concentration of long KRAS ctDNA fragments/concentration of short KRAS ctDNA fragments

Measure: Change in integrity index of circulating DNA for KRAS gene

Time: Nine timepoints between Day-1 to Day 3

Secondary Outcomes

Description: ng/mL in plasma

Measure: Change in plasma concentration of long (~ 290bp) fragments of ACTB gene

Time: Nine timepoints between Day-1 to Day 3

Description: ng/mL in plasma

Measure: Change in plasma concentration of short (~ 145bp) fragments of KRAS gene

Time: Nine timepoints between Day-1 to Day 3

Description: ng/mL in plasma

Measure: Change in plasma concentration of long (~ 300bp) fragments of KRAS gene

Time: Nine timepoints between Day-1 to Day 3

Description: ng/mL in plasma

Measure: Change in plasma concentration of mutant KRAS DNA fragments

Time: Nine timepoints between Day-1 to Day 3

Description: ng/mL in plasma

Measure: Change in plasma concentration of BRAF DNA fragments with V600E mutation

Time: Nine timepoints between Day-1 to Day 3

Time Perspective: Prospective

Case-Only


There is one SNP

SNPs


1 V600E

Change in plasma concentration of BRAF DNA fragments with V600E mutation. --- V600E ---



HPO Nodes


HPO:
Colon cancer
Genes 59
TP53 TRIP13 COL14A1 SMAD4 BRCA2 MLH1 MSH6 HABP2 PMS2 APC BUB1B PALLD BUB1 GREM1 NTHL1 PMS1 MSH6 AXIN2 APC EPCAM BUB3 MSH2 APC KRAS TGFBR2 FAN1 MINPP1 APC MSH3 SH3KBP1 TP53 KRAS AAGAB SMAD4 BMPR1A MSH2 BMPR1A MLH3 MSH2 PALB2 MUTYH FLCN PIK3CA BMPR1A FOXE1 MSH2 SMAD7 MLH1 CEP57 MLH1 BRCA1 RPS19 PRKAR1A PMS1 APC CDKN2A APC MLH1 APC
Neoplasm of the colon
Genes 83
SMAD4 KIT TP53 TRIP13 COL14A1 MDM2 SMAD4 POLE BRCA2 MLH1 MSH6 HABP2 PMS2 APC SDHC MUTYH BUB1B PALLD BUB1 GREM1 NTHL1 PMS1 PTEN STK11 SDHB MSH6 AXIN2 APC EPCAM BUB3 KIT AXIN2 MSH2 APC KRAS TGFBR2 SEMA4A POLD1 BMPR1A FAN1 PDGFRA MINPP1 APC MSH3 SH3KBP1 BMPR1A TP53 KRAS RNF43 AAGAB SMAD4 BMPR1A MSH2 BMPR1A CDKN2A BMPR1A MLH3 MSH2 PALB2 MUTYH FLCN SDHA PIK3CA BMPR1A FOXE1 MSH2 ENG SMAD7 MLH1 CEP57 CHEK2 MLH1 RPS20 BRCA1 TP53 RPS19 PRKAR1A PMS1 APC CDKN2A APC MLH1 APC